Hide Board Information

Show Board Information

Delphax Tech Inc DLPX

Board Mod: Phinehas

Asst Mods:

Last Post: 09/28/2021 4:13:51 PM

Board Marks: 0

Posts Today: 0

Board Views Today: 3

Delphax Tech Inc (OTCMRKTS: DLPX) Stock Message Board

1. DLPX Company Profile

    

2. DLPX Time & Sales

    

3. DLPX Recent News

    

4. DLPX Filings

    

5. DLPX Financials

    

6. DLPX Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

6	DLPX 68% v1,7M c.1429 f6,8M	znewcar1	09/28/2021 4:13:51 PM
5	DLPX 447% v2,3M c.1642 f6,8M	znewcar1	02/19/2021 4:02:55 PM
4	September 28, 2016 - Delphax Announces Strategic (1)	Phinehas	10/09/2016 6:46:01 PM
3	Latest Delphax Tech Inc (DLPX) Headlines Delphax	Stock_Tracker	03/09/2014 2:59:51 PM
2	DLPX 0.41 Stock Charts $DLPX 1 Month Chart	chartguy89	03/06/2014 8:52:03 PM
1	DLPX Stock Charts Last: UNCH Tuesday, February	chartguy89	02/25/2014 10:01:16 AM

Recent Articles

• Queclink Strengthens European Market with New Office Venture
• Jingle Pay Partners with Western Union for Global Transfers
• Ursa Major's New Hypersonic Engine Contract Boosts National Defense
• PayPal's Innovative Storefront Ads: Revolutionizing E-Commerce Reach
• Innovative AI Multimodal Learning Platform Set to Transform Learning
• Empowering Africa's Children Through Quality Education Initiatives
• Exploring the Evolution of Urban-Rural Transport in China
• DDB Capital Enhances Investment Focus in North Alabama Housing
• Anticipation Grows for the 2nd China-Central Asia Summit
• Revitalizing Heritage: A Journey Through Dunhuang's Culture
• Abbisko Therapeutics Advances Irpagratinib Study for HCC Treatment
• China to Host 6th Multinationals Summit, Encouraging Investment
• SDP Japan Secures $31 Million to Transform Surgical Care
• Tokyo Gas Triumphs in Cloud Native Case Study Competition
• Significant Subgroup Analysis of Cadonilimab in Cervical Cancer
• Stavian Chemical Achieves Major Milestone in Global Rankings
• ArkBio's Azstarys Approved for ADHD Treatment Review in China
• Strategic Thinking in China's Development Plans and Governance
• Industrial Lubricants: Insights and Future Market Trends Ahead
• Innovent's Mazdutide Advances with First Patient Dosed in Trial
• Innovative Treatment Strategies Highlighted at EHA 2025 Conference
• Celltrion Gains FDA Nod for New STEQEYMA® Pediatric Formulation
• Innovative Drug Screening Services Introduced by Samsung Biologics
• Transforming Transit: $4 Billion to Electrify Buses in Canada
• Abaxx Technologies Launches Innovative Gold Futures Trading
• 2025 Meijer LPGA Classic Makes Impact with $1.5 Million
• Bombardier's Global 7500 Establishes New Speed Benchmark
• IDEX Biometrics ASA Announces Significant Share Issuance to Personnel
• Investors Urged to Join Class Action Against West Pharmaceutical Services
• Honoring Leonard A. Lauder: A Legacy in Alzheimer's Research
• Elevate Your Earnings with PFMCrypto's Exciting XRP Giveaway
• AIXA Miner Celebrates Groundbreaking Milestone in Green Mining
• Oma Savings Bank Plc Revises Profit Outlook: Important Update
• Transformative Leadership Change at Renault Group Announced
• Deadline for Fortrea Holdings Inc. Investors in Lawsuit Ahead
• Dupixent® Triumphs in Phase 4 Trial Against Xolair® for CRSwNP
• Dupixent vs. Xolair: Breakthrough Findings in Asthma Treatment
• Faruqi & Faruqi Investigates Ibotta's Legal Claims for Investors
• Red Cat Holdings Faces Legal Challenges Amid Investor Concerns
• Investor Alert: Key Updates on Iovance Biotherapeutics Lawsuit
• Investors Alert: Faruqi & Faruqi Advocate for Open Lending Claims
• Compass Diversified Investors Encouraged to Act Before Deadline
• Freedom Holding Corp. Sees Strong Financial Growth in 2025
• Intellia's Lonvo-z Shows Promising Results for HAE Treatment
• Important Update for Rocket Pharmaceuticals Investors
• DoubleVerify Investors Urged to Consider Legal Options Now
• Investing in Zenas BioPharma: What Investors Should Know
• Deadline for NET Power Investors: What's Next After Losses?
• Investors Urged to Act: Krispy Kreme Legal Investigation Update
• Investigating Investor Claims on Avis Budget Group's Financials